Usability Testing of a Digital Assessment Routing Tool: Protocol for an Iterative Convergent Mixed Methods Study.
Usability Testing of a Digital Assessment Routing Tool: Protocol for an Iterative Convergent Mixed Methods Study.
复制标题
DOI：
10.2196/27205
复制
发表时间：
2021-05-18
影响因子：
1.7
通讯作者：
Morrissey D
中科院分区：
文献类型：
--
作者：
Lowe C;Hanuman Sing H;Browne M;Alwashmi MF;Marsh W;Morrissey D
肌肉骨骼疾病占全球残疾的16%，对数百万患者造成负面影响，并增加了医疗保健利用的负担。改善医疗保健结果和效率的数字技术被视为优先事项;然而，创新往往没有得到充分开发和采用。此外，它们很少在临床试验中进行足够严格的测试-临床疗效证明的金标准。我们开发了一种新的肌肉骨骼数字评估路由工具（DART），允许用户进行自我评估并指导正确的护理。DART需要进行可用性测试，为临床试验做准备。本研究将使用迭代收敛混合方法设计来评估和缓解所有严重的可用性问题，以优化用户体验和采用。使用这种方法，当DART被整合到临床管理路径中时，我们将为进展到全面随机对照试验提供合理的信心。本研究方案将为移动的医疗解决方案的未来可用性研究提供蓝图。我们将收集20-30名18岁及以上参与者的定性和定量数据，为期4个月。招募的受试者的确切数量将取决于达到研究终点所需的迭代周期数。在之前的内部测试和利益相关者参与的基础上，定量数据收集由ISO 9241-210-2019标准和系统可用性量表中的结构定义，为DART提供可用性评分。在参与者对定量问题的回答的指导下，研究者将把定性数据收集的重点放在特定的可用性问题上。然后将对这些进行分级，以提供在整个迭代周期中进一步改进DART系统的基本原理。本研究于2020年6月4日获得伦敦大学玛丽皇后学院研究伦理委员会的批准（QMREC 2018/48/048）。在稿件提交时，研究招募正在进行中，数据收集将于2021年完成，结果将于2021年发表。本研究将提供有关移动的医疗DART系统可用性和验收的证据，确定支持用户采用所需的系统改进，并最大限度地减少次优系统可用性作为后续非劣效性临床试验中的潜在混杂因素。成功应该产生一个安全有效的系统，具有出色的可用性，方便患者更快，更容易地获得适当的护理，同时减少初级和二级护理肌肉骨骼服务的负担。这种刻意严谨的移动的健康创新方法可以作为其他类似应用程序开发人员的指南。DERR1-10.2196/27205
Musculoskeletal conditions account for 16% of global disability, resulting in a negative effect on millions of patients and an increasing burden on health care utilization. Digital technologies that improve health care outcomes and efficiency are considered a priority; however, innovations are often inadequately developed and poorly adopted. Further, they are rarely tested with sufficient rigor in clinical trials—the gold standard for clinical proof of efficacy. We have developed a new musculoskeletal Digital Assessment Routing Tool (DART) that allows users to self-assess and be directed to the right care. DART requires usability testing in preparation for clinical trials. This study will use the iterative convergent mixed methods design to assess and mitigate all serious usability issues to optimize user experience and adoption. Using this methodology, we will provide justifiable confidence to progress to full-scale randomized controlled trials when DART is integrated into clinical management pathways. This study protocol will provide a blueprint for future usability studies of mobile health solutions. We will collect qualitative and quantitative data from 20-30 participants aged 18 years and older for 4 months. The exact number of participants recruited will be dependent on the number of iterative cycles required to reach the study end points. Building on previous internal testing and stakeholder involvement, quantitative data collection is defined by the constructs within the ISO 9241-210-2019 standard and the system usability scale, providing a usability score for DART. Guided by the participant responses to quantitative questioning, the researcher will focus the qualitative data collection on specific usability problems. These will then be graded to provide the rationale for further DART system improvements throughout the iterative cycles. This study received approval from the Queen Mary University of London Ethics of Research Committee (QMREC2018/48/048) on June 4, 2020. At manuscript submission, study recruitment was on-going, with data collection to be completed and results published in 2021. This study will provide evidence concerning mobile health DART system usability and acceptance determining system improvements required to support user adoption and minimize suboptimal system usability as a potential confounder within subsequent noninferiority clinical trials. Success should produce a safe effective system with excellent usability, facilitating quicker and easier patient access to appropriate care while reducing the burden on primary and secondary care musculoskeletal services. This deliberately rigorous approach to mobile health innovation could be used as a guide for other developers of similar apps. DERR1-10.2196/27205
登录
查看更多内容
影响因子：
5.3
作者：
Cruz Zapata, Belen;Luis Fernandez-Aleman, Jose;Toval, Ambrosio
通讯作者：
Toval, Ambrosio
DOI：
10.1016/s0140-6736(20)32340-0
发表时间：
2021-12-19
期刊：
Lancet (London, England)
影响因子：
--
作者：
Cieza A;Causey K;Kamenov K;Hanson SW;Chatterji S;Vos T
通讯作者：
Vos T
影响因子：
7.4
作者：
Greenhalgh T;Wherton J;Papoutsi C;Lynch J;Hughes G;A'Court C;Hinder S;Fahy N;Procter R;Shaw S
通讯作者：
Shaw S
DOI：
10.1016/s0140-6736(18)32335-3
发表时间：
2018-11-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
GBD 2017 DALYs and HALE Collaborators
通讯作者：
GBD 2017 DALYs and HALE Collaborators
影响因子：
9.7
作者：
Ashwood, J. Scott;Mehrotra, Ateev;Uscher-Pines, Lori
通讯作者：
Uscher-Pines, Lori